Phase 2 N=93 FACBC PET/CT for Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=205 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
Colorectal Cancer
Primary: Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death — 50.25 percentage of participants
Phase 3 N=588 Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
Essential Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -22.71; -16.11 mmHg
Phase 4 N=73 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel
Acne Vulgaris
Primary: Worst Postbaseline Tolerability (Erythema) — 25; 28; 27; 24 participants
Phase 2 N=73 The Alberta Diet: Effectiveness Study
Type 2 Diabetes
Primary: Change in Total Energy Intake — -178 kcal
Phase 2 N=22 Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Carcinoma, Non-Small-Cell Lung · Lung Neoplasms
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs With CALGB-ECTC Grade 3 or 4, TEAEs Leading to Discontinuation, TEAEs Leading…
Phase 2 N=907 An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
Systolic Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -20.89; -23.55; -21.26; -19.31 mmHg
Phase 3 N=508 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
Hypertension
Primary: Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28 — 390; 230 Subjects
N/A N=109 Multifocal High ADD Contact Lens Proof of Concept Trial
Presbyopia
Primary: High Contrast Visual Acuity (HCVA) Near Monocular — 0.18; 0.32 logMAR
Phase 1 N=16 Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
Parkinson's Disease (PD)
Primary: Cmax - Maximum Observed Plasma Concentration of Levodopa — 896; 1088; 1014; 889 ng/mL
Phase 2 N=30 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants
Phase 2 N=47 A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Rheumatoid Arthritis
Primary: Percentage of Participants With Any Infusion Reaction — 13.6; 12.0 Percentage of Participants
Phase 2 N=141 Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Trough Forced Expiratory Volume in One Second (FEV1) Response [L] After Four Weeks of Treatment. — 0.057; 0.055 Litres — p=0.8937
N/A N=13 Physical Activity in Children With Type 1 Diabetes Study
Type 1 Diabetes Mellitus · Physical Activity
Primary: Feasibility: Response Rate — 4; 4 number of participants
Phase 2 N=33 BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC
Non-Small Cell Lung Cancer
Primary: Response Rate — 11 participants